Author Altmann, Bettina

• 2011 | Conference Abstract
  ​ ​First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant​
  d'Amore, F.; da Silva, M. G.; Leppa, S.; Relander, T.; Pezzutto, A.; Lauritzsen, G. F. & Weidmann, E. et al.​ (2011)
  Blood, 118(21) ​53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)​, San Diego, CA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2012 | Conference Abstract
  ​ ​First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy​
  d'Amore, F.; Leppa, S.; da Silva, M. C.; Relander, T.; Brown, P. D. N.; Weidmann, E. & Lauritzsen, G. F. et al.​ (2012)
  Blood, 120(21) ​54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)​, Atlanta, GA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2014 | Conference Abstract
  ​ ​USP9X promotes resistance to spindle poisons in Diffuse Large B Cell Non Hodgkin's Lymphoma by regulating the mitotic cell fate decision​
  Engel, K.; Kurutz, J.; Rudelius, M.; Altmann, B.; Fernandez-Saiz, V.; Brunner, A. & Targosz, B.-S. et al.​ (2014)
  Oncology Research and Treatment, 37 pp. 69​-70. 
  Basel​: Karger.
  ​Details  WoS 

• 2015 | Conference Abstract
  ​ ​Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R-CHOP​
  Hohloch, K.; Altmann, B.; Pfreundschuh, M.; Loeffler, M.; Schmitz, N.; Ziepert, M. & Truemper, L. H.​ (2015)
  Blood, 126(23) ​57th Annual Meeting of the American-Society-of-Hematology​, Orlando, FL.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2016 | Journal Article
  ​ ​Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL.​
  Zettl, F.; Ziepert, M.; Altmann, B.; Zeynalova, S.; Loeffler, M.; Schmitz, N. & Pfreundschuh, M. et al.​ (2016) 
  Journal of Clinical Oncology, 34(15_suppl) pp. 7539​-7539​.​ DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.7539 
  ​Details  DOI 

• 2016 | Journal Article | 
  ​ ​USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma​
  Engel, K.; Rudelius, M.; Slawska, J.; Jacobs, L.; Abhari, B. A.; Altmann, B. & Kurutz, J. et al.​ (2016) 
  EMBO Molecular Medicine, 8(8) pp. 851​-862​.​ DOI: https://doi.org/10.15252/emmm.201506047 
  ​Details  DOI  PMID  PMC  WoS 

• 2017 | Journal Article
  ​ ​Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.​
  Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
  Journal of Clinical Oncology, 35(15_suppl) pp. 7539​-7539​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7539 
  ​Details  DOI 

• 2017 | Journal Article
  ​ ​Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.​
  Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
  Journal of Clinical Oncology, 35(15_suppl) pp. 7506​-7506​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7506 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant​
  d'Amore, F.; Leppä, S.; Silva, M. G. da; Relander, T.; Lauritzsen, G. F.; Brown, P. D. N. & Pezzutto, A. et al.​ (2018) 
  Blood, 132(Supplement 1) pp. 998​-998​.​ DOI: https://doi.org/10.1182/blood-2018-99-110429 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.​
  Pfreundschuh, M.; Murawski, N.; Ziepert, M.; Altmann, B.; Dreyling, M. H.; Borchmann, P. & Luminari, S. et al.​ (2018) 
  Journal of Clinical Oncology, 36(15_suppl) pp. 7574​-7574​.​ DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.7574 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA​
  Poeschel, V.; Held, G.; Ziepert, M.; Altmann, B.; Witzens-Harig, M.; Holte, H. & Thurner, L. et al.​ (2018) 
  Blood, 132(Supplement 1) pp. 781​-781​.​ DOI: https://doi.org/10.1182/blood-2018-99-112403 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study​
  Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Hänel, M. & Truemper, L. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 1589​-1589​.​ DOI: https://doi.org/10.1182/blood-2019-123637 
  ​Details  DOI 

• 2020 | Journal Article
  ​ ​Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial​
  Wulf, G. G. ; Altmann, B.; Ziepert, M.; D’Amore, F.; Held, G.; Greil, R. & Tournilhac, O. et al.​ (2020) 
  Leukemia,.​ DOI: https://doi.org/10.1038/s41375-020-0838-5 
  ​Details  DOI 

• 2020 | Journal Article | Research Paper | 
  ​ ​Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group​
  Høhloch, K. ; Ziepert, M.; Trümper, L. ; Buske, C.; Held, G.; Poeschel, V. & Chapuy, B.  et al.​ (2020) 
  eJHaem, 1(1) pp. 181​-187​.​ DOI: https://doi.org/10.1002/jha2.61 
  ​Details  DOI 

• 2020 | Journal Article | 
  ​ ​Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)​
  Zettl, F.; Ziepert, M.; Altmann, B.; Zeynalova, S.; Held, G.; Pöschel, V. & Hohloch, K.  et al.​ (2020) 
  Annals of Hematology, 100(4) pp. 1031​-1038​.​ DOI: https://doi.org/10.1007/s00277-020-04345-3 
  ​Details  DOI 

• 2021 | Journal Article
  ​ ​Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial​
  Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Haenel, M. & Truemper, L. et al.​ (2021) 
  The Lancet Haematology, 8(4) pp. e267​-e277​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00022-3 
  ​Details  DOI 

• 2022 | Journal Article
  ​ ​KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials​
  Kaddu-Mulindwa, D.; Altmann, B.; Robrecht, S.; Ziepert, M.; Regitz, E.; Tausch, E. & Held, G. et al.​ (2022) 
  The Lancet Haematology, 9(2) pp. e133​-e142​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00369-0 
  ​Details  DOI 

• 2022 | Journal Article
  ​ ​First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial​
  Braulke, F.; Zettl, F.; Ziepert, M.; Viardot, A.; Kahl, C.; Prange-Krex, G. & Korfel, A. et al.​ (2022) 
  HemaSphere, 6(12) art. e808​.​ DOI: https://doi.org/10.1097/HS9.0000000000000808 
  ​Details  DOI  WoS 

Researcher

Sort

Items per Page